Cytokines profile in serum of homozygous familial hypercholesterolemia is changed by LDL-apheresis

Cytokine

Volumn 55, Issue 2, 2011, Pages 245-250

  Stefanutti, C ^a   Vivenzio, A ^a   Di Giacomo, S ^a   Ferraro, P M ^b  

^a POLICLINICO UMBERTO I   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Atherosclerosis; Cytokines; Homozygous familial hypercholesterolemia; Inflammation; LDL apheresis

Indexed keywords

DEXTRAN SULFATE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 1ALPHA; INTERLEUKIN 4; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; PADGEM PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ADOLESCENT; ADULT; ANTIINFLAMMATORY ACTIVITY; AORTA VALVE DISEASE; APHERESIS; ARTICLE; CARDIOVASCULAR RISK; CHILD; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SCHOOL CHILD; THERAPY EFFECT; TREATMENT DURATION;

ADOLESCENT; ADULT; BLOOD COMPONENT REMOVAL; CHILD; CHOLESTEROL, LDL; CYTOKINES; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIMIT OF DETECTION; LIPOPROTEINS, LDL; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 79959548062     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.04.003     Document Type: Article

References (40)

1. Tedgui A., Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006, 86:515-581.
2. Stefanutti C., Di Giacomo S., Vivenzio A., Isacchi G.C., Masella R., Caprari P., et al. Acute and long-term effects of low-density lipoprotein (LDL)-apheresis on oxidative damage to LDL and reducing capacity of erythrocytes in patients with severe familial hypercholesterolaemia. Clin Sci 2001, 100(2):191-198.
3. Cavaillon J.M., Adib-Conquy M., Fitting C., Adrie C., Payen D. Cytokine cascade in sepsis. Scand J Infect Dis 2003, 35:535-544.
4. Descoteaux A., Matlashewski G. Regulation of tumor necrosis factor gene expression and protein synthesis in murine macrophages treated with recombinant tumor necrosis factor. J Immunol 1990, 145:846-853.
5. Dinarello C.A., Ikejima T., Warner S.J., Orencole S.F., Lonnemann G., Cannon J.G., et al. Interleukin 1 induces interleukin 1. I. induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol 1987, 139:1902-1910.
6. Reilly M.P., Lehrke M., Wolfe M.L., Rohatgi A., Lazar M.A., Rader D.J. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005, 111:932-939.
7. Schreyer S.A., Peschon J.J., Leboeuf R.C. Accelerated atherosclerosis in mice lacking tumor necrosis factor receptor p55. J Biol Chem 1996, 271:26174-26178.
8. Schreyer S.A., Vick C.M., LeBoeuf R.C. Loss of lymphotoxin-alpha but not tumor necrosis factor-alpha reduces atherosclerosis in mice. J Biol Chem 2002, 277:12364-12368.
9. Dewberry R., Holden H., Crossman D., Francis S. Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. Arterioscler Thromb Vasc Biol 2000, 20:2394-2400.
10. Cybulsky M.I., Iiyama K., Li H., Zhu S., Chen M., Iiyama M., et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001, 107:1255-1262.
11. Galea P., Thibault G., Lacord M., Bardos P., Lebranchu Y. IL-4, but not tumor necrosis factor-α, increases endothelial cell adhesiveness for lymphocytes by activating a cAMP-dependent pathway. J Immunol 1993, 151:588-596.
12. Lee Y.W., Kuhn H., Hennig B., Neish A.S., Toborek M. IL-4-induced oxidative stress upregulates VCAM-1 gene expression in human endothelial cells. J Mol Cell Cardiol 2001, 33:83-94.
13. Luscinskas F.W., Kansas G.S., Ding H., Pizcueta P., Schleiffenbaum B.E., Tedder T.F., et al. Monocyte rolling, arrest and spreading on IL-4-activated vascular endothelium under flow is mediated via sequential action of L-selectin, beta(1)-integrins, and beta(2)-integrins. J Cell Biol 1994, 125:1417-1427.
14. Rollins B.J., Pober J.S. Interleukin-4 induces the synthesis and secretion of mcp-1/je by human endothelial cells. Am J Pathol 1991, 138:1315-1319.
15. King V.L., Szilvassy S.J., Daugherty A. Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor-/-mice. Arterioscler Thromb Vasc Biol 2002, 22:456-461.
16. Mallat Z., Heymes C., Ohan J., Faggin E., Lesèche G., Tedgui A. Expression of interleukin-10 in human atherosclerotic plaques. Relation to inducible nitric oxide synthase expression and cell death. Arterioscler Thromb Vasc Biol 1999, 19:611-616.
17. Uyemura K., Demer L.L., Castle S.C., Jullien D., Berliner J.A., Gately M.K., et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 1996, 97:2130-2138.
18. Dihazi H., Koziolek M.J., Sollner T., Kahler E., Klingel R., Neuhoff R., et al. Protein adsorption during LDL-apheresis: proteomic analysis. Nephrol Dial Transplant 2008, 23:2925-2935.
19. Suzuki M., Yamane S., Matsugane T., Nobuto T., Azuma N., Nishide T., et al. Evaluation of double filtration plasmapheresis, thermofiltration, and low-density lipoprotein adsorptive methods by crossover test in the treatment of familial hypercholesterolemia patients. Artif Organs 1996, 20(4):296-302.
20. Sampietro T., Tuoni M., Ferdeghini M., Ciardi A., Marraccini P., Prontera C., et al. Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia. Circulation 1997, 96(5):1381-1385.
21. Rovers C., Netea M.G., de Bont N., Demacker P.N., Jacobs C., Kullberg B.J., et al. Stalenhoef AF. LPS-induced cytokine production and expression of beta2-integrins and CD14 by peripheral blood mononuclear cells of patients with homozygous familial hypercholesterolemia. Atherosclerosis 1998, 141(1):99-105.
22. Kojima S., Shida M., Tanaka K., Takano H., Yokoyama H., Kuramochi M. Acute changes in plasma levels of hepatocyte growth factor during low-density lipoprotein apheresis. Ther Apher 2001, 5(1):2-6.
23. Kojima S., Shida M., Yokoyama H. Changes in C-reactive protein plasma levels during low-density lipoprotein apheresis. Ther Apher Dial 2003, 7(4):431-434.
24. Nakamura T., Kawagoe Y., Matsuda T., Takahashi Y., Sekizuka K., Ebihara I., et al. Effects of LDL apheresis and vitamin E-modified membrane on carotid atherosclerosis in hemodialyzed patients with arteriosclerosis obliterans. Kidney Blood Press Res 2003, 26(3):185-191.
25. Bláha M., Krejsek J., Bláha V., Andrýs J., Vokurková D., Malý J., et al. Selectins and monocyte chemotactic peptide as the markers of atherosclerosis activity. Physiol Res 2004, 53(3):273-278.
26. Kobayashi S., Moriya H., Maesato K., Okamoto K., Ohtake T. LDL-apheresis improves peripheral arterial occlusive disease with an implication for anti-inflammatory effects. J Clin Apher 2005, 20(4):239-243.
27. Utsumi K., Kawabe M., Hirama A., Ueda K., Kamada Y., Arii K., et al. Effects of selective LDL apheresis on plasma concentrations of ICAM-1, VCAM-1 and P-selectin in diabetic patients with arteriosclerosis obliterans and receiving maintenance hemodialysis. Clin Chim Acta 2007, 377(1-2):198-200.
28. Otto C., Berster J., Otto B., Parhofer K.G. Effects of two whole blood systems (DALI and Liposorber D) for LDL apheresis on lipids and cardiovascular risk markers in severe hypercholesterolemia. J Clin Apher 2007, 22(6):301-305.
29. Hovland A., Hardersen R., Sexton J., Mollnes T.E., Lappegård K.T. Different inflammatory responses induced by three LDL-lowering apheresis columns. J Clin Apher 2009, 24(6):247-253.
30. Zheng X.X., Steele A.W., Nickerson P.W., Steurer W., Steiger J., Strom T.B., et al. Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation. J Immunol 1995, 154:5590.
31. Li W., Lu L., Li Y., Fu F., Fung J.J., Thomson A.W., et al. High-dose cellular IL-10 exacerbates rejection and reverses effects of cyclosporine and tacrolimus in mouse cardiac transplantation. Transplant Proc 1997, 29:1081.
32. Rosenbaum J.T., Angell E. Paradoxical effects of IL-10 in endotoxin-induced uveitis. J Immunol 1995, 155:4090.
33. Wogensen L., Lee M.S., Sarvetnick N. Production of interleukin-10 by islet cells accelerates immune-mediated destruction of β cells in nonobese diabetic mice. J Exp Med 1994, 179:1379.
34. Moritani M., Yoshimoto K., Tashiro F., Hashimoto C., Miyazaki J., Li S., et al. Transgenic expression of IL-10 in pancreatic islet A cells accelerates autoimmune insulitis and diabetes in non-obese diabetic mice. Int Immunol 1994, 6:1927.
35. Berman R.M., Suzuki T., Tahara H., Robbins P.D., Narula S.K., Lotze M.T. Systemic administration of cellular IL-10 induces an effective specific and long-lived immune response against established tumor in mice. J Immunol 1996, 157:231.
36. Adib-Conquy M., Petit A., Marie C., Fitting C., Cavaillon J. Paradoxical priming effects of IL-10 on cytokine production. Int Immunol 1996, 11(5):689-698.
37. Di Carlo E., Coletti A., Modesti A., Giovarelli M., Forni G., Musiani P. Local release of interleukin-10 by transfected mouse adenocarcinoma cells exhibits pro- and anti-inflammatory activity and results in a delayed tumor rejection. Eur Cytokine Netw 1998, 9:61.
38. Chernoff A., Granowitz E., Shapiro L., Vannier E., Lonnemann G., Angel J., et al. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 1995, 154:5492.
39. Huhn R.D., Radwanski E., O'Connell S.M., Sturgill M.G., Clarke L., Cody R.P., et al. Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood 1996, 87:699.
40. Klinke D. The bioactivity of Il-12: there's more to the story than P70 or P40. J Immunol 2000, 165(4):1877-1881.